Format

Send to

Choose Destination
Bone. 2015 Mar;72:53-64. doi: 10.1016/j.bone.2014.11.009. Epub 2014 Nov 20.

Lack of prolidase causes a bone phenotype both in human and in mouse.

Author information

1
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
2
Bone Metabolic Unit, San Raffaele Scientific Institute, Milan, Italy.
3
University of Sheffield, Sheffield, UK.
4
Department of Drug Sciences, University of Pavia, Pavia, Italy.
5
Pediatric Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
6
Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
7
Department of Pediatrics, Turgut Ozal University, Ankara, Turkey.
8
Department of Pediatrics, Hacettepe University, Ankara, Turkey.
9
Department of Dermatology, Medical University of Warsaw, Poland.
10
Gazi University Hospital, Pediatric Metabolic Unit, Ankara, Turkey.
11
Unit of Rare Diseases, Department of Pediatrics, Gaslini Institute, Genoa, Italy.
12
Basic Research Laboratory, Center for Cancer Research, NCI at Frederick, Frederick, MD, USA.
13
McLaughlin Research Institute, Great Falls, MT, USA.
14
Department of Molecular Medicine, University of Pavia, Pavia, Italy. Electronic address: aforlino@unipv.it.

Abstract

The degradation of the main fibrillar collagens, collagens I and II, is a crucial process for skeletal development. The most abundant dipeptides generated from the catabolism of collagens contain proline and hydroxyproline. In humans, prolidase is the only enzyme able to hydrolyze dipeptides containing these amino acids at their C-terminal end, thus being a key player in collagen synthesis and turnover. Mutations in the prolidase gene cause prolidase deficiency (PD), a rare recessive disorder. Here we describe 12 PD patients, 9 of whom were molecularly characterized in this study. Following a retrospective analysis of all of them a skeletal phenotype associated with short stature, hypertelorism, nose abnormalities, microcephaly, osteopenia and genu valgum, independent of both the type of mutation and the presence of the mutant protein was identified. In order to understand the molecular basis of the bone phenotype associated with PD, we analyzed a recently identified mouse model for the disease, the dark-like (dal) mutant. The dal/dal mice showed a short snout, they were smaller than controls, their femurs were significantly shorter and pQCT and ╬╝CT analyses of long bones revealed compromised bone properties at the cortical and at the trabecular level in both male and female animals. The differences were more pronounce at 1 month being the most parameters normalized by 2 months of age. A delay in the formation of the second ossification center was evident at postnatal day 10. Our work reveals that reduced bone growth was due to impaired chondrocyte proliferation and increased apoptosis rate in the proliferative zone associated with reduced hyperthrophic zone height. These data suggest that lack of prolidase, a cytosolic enzyme involved in the final stage of protein catabolism, is required for normal skeletogenesis especially at early age when the requirement for collagen synthesis and degradation is the highest.

KEYWORDS:

Bone phenotype; Collagen; Growth plate; Prolidase; Prolidase deficiency

PMID:
25460580
DOI:
10.1016/j.bone.2014.11.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center